- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | NewcelX Ltd.: NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | 473 | PR Newswire |
ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine... ► Artikel lesen | |
| 12.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX: Patent für neurologische Therapien in China veröffentlicht | 4 | Investing.com Deutsch | ||
| 11.12.25 | NewcelX patent for neurological disease treatments published in China | 2 | Investing.com | ||
| 17.11.25 | NewcelX appoints ALS specialist to scientific advisory board | 1 | Investing.com | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 17.11.25 | NewcelX Ltd.: NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute | 152 | PR Newswire | ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| 17.11.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11.25 | Neurology expert Prof. Ben-Hur joins NewcelX scientific board | 2 | Investing.com | ||
| 04.11.25 | NewcelX Ltd.: NewcelX CEO Issues Letter to Shareholders | 179 | PR Newswire | ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies... ► Artikel lesen | |
| 03.11.25 | NewcelX Ltd.: NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. | 252 | PR Newswire | ZURICH, Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based... ► Artikel lesen | |
| 03.11.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10.25 | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger / Combined Company Re-Named NewcelX Ltd. | 574 | PR Newswire | Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"
ZURICH and NESS ZIONA... ► Artikel lesen | |
| 30.10.25 | NSE/A - NLS Pharmaceutics Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 30.10.25 | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.10.25 | NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger | 692 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system... ► Artikel lesen | |
| 29.10.25 | NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem | 296 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 29.10.25 | NLS Pharmaceutics to execute 1-for-10 reverse share split | 1 | Seeking Alpha | ||
| 29.10.25 | NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares | 322 | PR Newswire | ZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,250 | -3,65 % | Qiagen-Aktie: Kommt jetzt die massive Übernahme? | Die Qiagen-Aktie schoss zuletzt massiv nach oben und setzt am Mittwoch ihre Aufwärtsbewegung fort. Dahinter stecken Übernahmegerüchte. Das müssen Anleger jetzt wissen. Neue Übernahmefantasie 2020 war... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 93,79 | +3,04 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| CG ONCOLOGY | 57,13 | +4,46 % | CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| BIONTECH | 100,90 | -0,10 % | BioNTech-Aktie: Kommt jetzt der große Durchbruch? | Es sieht nach einer Trendwende bei der BioNTech-Aktie aus. Nachdem das Mainzer Biotech-Unternehmen 2025 eine ziemlich schwache Börsenperformance lieferte, zog der Aktienkurs in den ersten Tagen des... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ALUMIS | 26,680 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| PRAXIS PRECISION MEDICINES | 312,60 | -3,54 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| KYMERA THERAPEUTICS | 70,74 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) | ||
| BEAM THERAPEUTICS | 31,120 | 0,00 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| KINIKSA PHARMACEUTICALS | 41,830 | +1,95 % | Kiniksa Pharmaceuticals beruft neuen COO und Chief Strategy Officer | ||
| SUMMIT THERAPEUTICS | 16,850 | 0,00 % | Summit Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und Kursziel von 40 US-Dollar | ||
| ERASCA | 10,050 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,770 | +2,10 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| IMMUNOME | 24,870 | +4,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung |
NEWCELX LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.